FIGURE 2 from Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC

ALK resistance mutations observed in clinical (n = 26; A) and liquid biopsy (n = 202; B) cohorts, by patient (columns) and grouped by EML4-ALK variant type. Filled regions of the oncoprint indicate presence of the ALK resistance mutation designated by the row name for a given patient. Resistance mutation percentages indicate share of each among total patients, by cohort. Both G1202R and I1171N are associated with EML4-ALK v3 and L1196M is associated with EML4-ALK non-v3.